Danaher Corporation $DHR Position Boosted by Breakwater Capital Group

Breakwater Capital Group grew its position in Danaher Corporation (NYSE:DHR) by 522.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,984 shares of the conglomerate’s stock after purchasing an additional 8,381 shares during the period. Breakwater Capital Group’s holdings in Danaher were worth $2,212,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Legacy Wealth Asset Management LLC acquired a new stake in shares of Danaher in the third quarter worth $2,812,000. Chapin Davis Inc. acquired a new position in shares of Danaher during the 3rd quarter valued at $957,000. Hardin Capital Partners LLC purchased a new stake in Danaher during the 3rd quarter worth $626,000. Pacifica Partners Inc. purchased a new stake in Danaher during the 3rd quarter worth $239,000. Finally, Stableford Capital II LLC increased its holdings in Danaher by 292.4% in the 3rd quarter. Stableford Capital II LLC now owns 18,766 shares of the conglomerate’s stock valued at $4,158,000 after purchasing an additional 13,984 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

DHR opened at $217.33 on Friday. The company has a market capitalization of $152.78 billion, a P/E ratio of 38.60, a PEG ratio of 2.72 and a beta of 0.76. The company has a 50-day moving average of $210.88 and a 200-day moving average of $194.44. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.77 earnings per share. Equities analysts expect that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s dividend payout ratio is presently 28.42%.

Analysts Set New Price Targets

DHR has been the topic of several research reports. The Goldman Sachs Group raised their price objective on Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Barclays raised their target price on Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a report on Wednesday. UBS Group initiated coverage on shares of Danaher in a research report on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price objective for the company. Guggenheim boosted their target price on shares of Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Finally, Royal Bank Of Canada upped their target price on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $235.23.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.